Get notified when HRMY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — The Chief Financial Officer departed effective July 16, 2026, to pursue other career opportunities, creating a leadership transition during a period of strong revenue growth.
Harmony Biosciences CFO Glenn Reicin departs; Q2 revenue hits record $261M, up 30% YoY
Filed July 16, 2026 · Period ending July 16, 2026 · ~1 min read
Key Changes
-
high
CFO Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities; SVP Stephen Mollichella appointed Interim Principal Financial Officer while the company searches for a permanent CFO.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Preliminary Q2 2026 WAKIX net revenue of approximately $261M represents a quarterly record, up 30% year-over-year and 21% sequentially from Q1 2026, driven by strong demand and commercial execution.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
Full-year 2026 net product revenue guidance reaffirmed at $1.0B to $1.04B based on first-half performance and current business trends.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Partner
Trade HRMY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 20, 2026 · How we verify